Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 2 years, with Jun 2024 value amounting to $166.8 million.

  • Rhythm Pharmaceuticals' Total Non-Current Liabilities rose 31.99% to $166.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $166.8 million, marking a year-over-year increase of 31.99%. This contributed to the annual value of $161.8 million for FY2023, which is 38.46% up from last year.
  • According to the latest figures from Q2 2024, Rhythm Pharmaceuticals' Total Non-Current Liabilities is $166.8 million, which was up 2.64% from $162.5 million recorded in Q1 2024.
  • Rhythm Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $166.8 million for Q2 2024, and its period low was $80.5 million during Q2 2022.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Total Non-Current Liabilities value was $126.3 million (recorded in 2023), while the average stood at $133.7 million.
  • Data for Rhythm Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY surged of 57.03% (in 2023) over the last 5 years.
  • Over the past 3 years, Rhythm Pharmaceuticals' Total Non-Current Liabilities (Quarterly) stood at $116.9 million in 2022, then spiked by 38.46% to $161.8 million in 2023, then spiked by 31.99% to $166.8 million in 2024.
  • Its last three reported values are $166.8 million in Q2 2024, $162.5 million for Q1 2024, and $161.8 million during Q4 2023.